deltatrials
Completed PHASE3 NCT00240773

A Safety and Effectiveness Study of Acetaminophen (4000 mg/Day) and Naproxen (750 mg/Day) in the Treatment of Osteoarthritis of the Hip or Knee

A Randomized, Double-Blind, Long-Term Comparative Study Evaluating the Safety and Efficacy of Acetaminophen (4000 mg/Day) and Naproxen (750 mg/Day) in the Treatment of Osteoarthritis of the Hip or Knee

Sponsor: Johnson & Johnson Consumer and Personal Products Worldwide

Conditions Osteoarthritis, Hip Osteoarthritis, Knee
Interventions acetaminophen naproxen
Updated 5 times since 2017 Last updated: Jun 18, 2015 Completion: Jun 30, 2003

Listed as NCT00240773, this PHASE3 trial focuses on Osteoarthritis, Hip and Osteoarthritis, Knee and remains completed. Sponsored by Johnson & Johnson Consumer and Personal Products Worldwide, it has been updated 5 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Johnson & Johnson Consumer and Personal Products Worldwide
  • McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Data source: Johnson & Johnson Consumer and Personal Products Worldwide

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.